Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment

X
Trial Profile

An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pasireotide (Primary) ; Pasireotide (Primary) ; Cabergoline
  • Indications Acromegaly; Dumping syndrome; Pituitary ACTH hypersecretion
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals; Recordati
  • Most Recent Events

    • 19 Jan 2024 This trial has been completed in France (Global end date: 25 July 2023).
    • 23 Sep 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
    • 18 Jun 2023 8-year interim results assessing long-term safety of pasireotide, presented at the 105th Annual Meeting of the Endocrine Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top